Assessing Copy Number Aberrations and Copy-Neutral Loss-of-Heterozygosity Across the Genome as Best Practice: An Evidence-Based Review from the Cancer Genomics Consortium (CGC) Working Group for Chronic Lymphocytic Leukemia

Publication date: Available online 16 October 2018Source: Cancer GeneticsAuthor(s): Kathy Chun, Gail D. Wenger, Alka Chaubey, D.P. Dash, Rashmi Kanagal-Shamanna, Sibel Kanturci, Ravindra Kolhe, Daniel L. Van Dyke, Lu Wang, Daynna J. Wolff, Patricia M. MironAbstractThe prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration. Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyotypes and multiple clones. Whole genome copy number assessment, currently performed by chromosomal microarray analysis (CMA), is particularly relevant in CLL for the following reasons: 1) copy number alterations (CNAs) represent key events with biologic and prognostic significance; 2) DNA from fresh samples is generally available; and 3) the tumor burden tends to be relatively high in peripheral blood. CMA also identifies novel copy number variants and copy-neutral loss-of-heterozygosity (CN-LOH), and can refine deletion breakpoints. The Cancer Genomics Consortium (CGC) Working Group for CLL has performed an extensive literature review to describe the evidence-based clinical utility of CMA in CLL. We provide suggestions for the integration of CMA into clinical use and list recurrent copy number alterations, regions of CN-LOH and mutated genes to aid in inter...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research